Clearside Biomedical Announces New Chairperson Appointment

Clearside Biomedical ( (CLSD) ) has shared an announcement.

On February 7, 2025, Clearside Biomedical was notified by Nasdaq about non-compliance with the minimum bid price requirement, risking delisting. The company plans to request a hearing to maintain its listing and has filed for a reverse stock split to regain compliance. Additionally, Anthony Gibney resigned as Chairperson on August 11, 2025, succeeded by Clay B. Thorp.

The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Spark’s Take on CLSD Stock

According to Spark, TipRanks’ AI Analyst, CLSD is a Underperform.

Clearside Biomedical’s overall stock score is driven primarily by severe financial weaknesses, including declining revenues and negative equity, which pose substantial risks. Technical analysis reflects bearish sentiment and oversold conditions, while valuation concerns are exacerbated by negative profitability. Although strategic alternatives are being explored, the negative sentiment associated with these events further pressures the stock.

To see Spark’s full report on CLSD stock, click here.

More about Clearside Biomedical

Clearside Biomedical, Inc. operates in the biopharmaceutical industry, focusing on developing and delivering treatments for eye diseases. The company’s primary products involve innovative therapies administered through the suprachoroidal space, targeting conditions like macular edema and uveitis.

Average Trading Volume: 4,465,697

Technical Sentiment Signal: Sell

Current Market Cap: $34.07M

For an in-depth examination of CLSD stock, go to TipRanks’ Overview page.